PARP1 and neoplasm: These findings are in trend with former evidence showing that the pharmacological inhibition of Werner syndrome helicase sensitizes cervical cancer and osteosarcoma cells to the telomeric G4 ligand telomestatin [84] as well as that the treatment of mice bearing human colon cancer xenografts with a combination of RHPS4 and a PARP inhibitor resulted in a greater reduction in tumor growth and in a longer survival rate with respect to animal that had received the single agents [79].